- Home
- MRSN vs KRON Comparison
MRSN vs KRON Comparison
Compare MRSN & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- KRON
- Stock Information
- Founded
- MRSN 2001
- KRON 2017
- Country
- MRSN United States
- KRON United States
- Employees
- MRSN N/A
- KRON N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- KRON Medicinal Chemicals and Botanical Products
- Sector
- MRSN Health Care
- KRON Health Care
- Exchange
- MRSN Nasdaq
- KRON Nasdaq
- Market Cap
- MRSN 71.9M
- KRON 61.5M
- IPO Year
- MRSN 2017
- KRON 2020
- Fundamental
- Price
- MRSN $0.53
- KRON $1.00
- Analyst Decision
- MRSN Buy
- KRON Buy
- Analyst Count
- MRSN 7
- KRON 3
- Target Price
- MRSN $6.00
- KRON $1.63
- AVG Volume (30 Days)
- MRSN 5.4M
- KRON 226.0K
- Earning Date
- MRSN 03-07-2025
- KRON 03-20-2025
- Dividend Yield
- MRSN N/A
- KRON N/A
- EPS Growth
- MRSN N/A
- KRON N/A
- EPS
- MRSN N/A
- KRON N/A
- Revenue
- MRSN $34,837,000.00
- KRON $9,864,000.00
- Revenue This Year
- MRSN N/A
- KRON $62.21
- Revenue Next Year
- MRSN N/A
- KRON N/A
- P/E Ratio
- MRSN N/A
- KRON N/A
- Revenue Growth
- MRSN N/A
- KRON 146.48
- 52 Week Low
- MRSN $0.49
- KRON $0.69
- 52 Week High
- MRSN $6.28
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- MRSN 32.86
- KRON 50.71
- Support Level
- MRSN $0.56
- KRON $0.97
- Resistance Level
- MRSN $0.82
- KRON $1.03
- Average True Range (ATR)
- MRSN 0.07
- KRON 0.05
- MACD
- MRSN 0.03
- KRON 0.00
- Stochastic Oscillator
- MRSN 8.39
- KRON 65.52
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.